Avacta Group has announced the successful completion of the sixth dose escalation cohort in its ALS-6000-101 Phase 1 clinical trial. The trial is evaluating the safety and tolerability of AVA6000, a tumour targeted form of doxorubicin that has been chemically modified with Avacta's pre|CISION platform. The data from the sixth cohort show an excellent safety profile for AVA6000, with a significant reduction in tumour volume confirmed in a patient with soft tissue sarcoma. The drug continues to be well tolerated by patients, demonstrating the potential for higher doses and more frequent dosing compared to doxorubicin. The Safety Data Monitoring Committee has recommended continuation to the seventh dose cohort. The company has adapted its clinical development strategy to bring forward the start of a potentially pivotal Phase 2 study in soft tissue sarcoma. Avacta intends to begin a short study to explore more frequent dosing of AVA6000 as a first-line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023, subject to regulatory approval. The company expects to publish detailed data from the Phase 1 study in Q4 2023.